% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Port:1010513,
author = {Port, M. and Barquinero, J-F. and Endesfelder, D. and
Moquet, J. and Oestreicher, U. and Terzoudi, G. and
Trompier, F. and Vral, A. and Abe, Y. and Ainsbury, L. and
Alkebsi, L. and Amundson, S. A. and Badie, C. and Baeyens,
A. and Balajee, A. S. and Balázs, K. and Barnard, S. and
Bassinet, C. and Beaton-Green, L. A. and Beinke, C. and
Bobyk, L. and Brochard, P. and Ciesielski, B. and Cuceu, C.
and Discher, M. and D,Oca, M. C. and Domínguez, I. and
Doucha-Senf, S. and Dumitrescu, A. and Duy, P. N. and Finot,
F. and Garty, G. and Ghandhi, S. A. and Gregoire, E. and
Goh, V. S. T. and Güçlü, I. and Hadjiiska, L. and
Hargitai, R. and Hristova, R. and Ishii, K. and Kis, E. and
Juniewicz, M. and Kriehuber, R. and Lacombe, J. and Lee, Y.
and Lopez Riego, M. and Lumniczky, K. and Mai, T. T. and
Maltar-Strmečki, N. and Marrale, M. and Martinez, J. S. and
Marciniak, A. and Maznyk, N. and McKeever, S. W. S. and
Meher, P. K. and Milanova, M. and Miura, T. and Monteiro
Gil, O. and Montoro, A. and Moreno Domene, M. and Mrozik, A.
and Nakayama, R. and O'Brien, G. and Oskamp, D. and Ostheim,
P. and Pajic, J. and Pastor, N. and Patrono, C. and Prieto
Rodriguez, M. J. and Pujol-Canadell, M. and Repin, M. and
Romanyukha, A. and Rößler, U. and Sabatier, L. and Sakai,
A. and Scherthan, H. and Schüle, S. and Seong, K. M. and
Sevriukova, O. and Sholom, S. and Sommer, S. and Suto, Y.
and Sypko, T. and Szatmári, T. and Takahashi-Sugai, M. and
Takebayashi, K. and Testa, A. and Testard, I. and Tichy, A.
ii A. and Triantopoulou, S. and Tsuyama, N. and
Unverricht-Yeboah, M. and Valente, M. and Van Hoey, O. and
Wilkins, R. C. and Wojcik, A. and Wojewodzka, M. and
Younghyun, Lee and Zafiropoulos, D. and Abend, M.},
title = {{RENEB} {I}nter-{L}aboratory {C}omparison 2021:
{I}nter-{A}ssay {C}omparison of {E}ight {D}osimetry
{A}ssays},
journal = {Radiation research},
volume = {199},
number = {6},
issn = {0033-7587},
address = {Great Falls, Va.},
publisher = {Radiation Research Society},
reportid = {FZJ-2023-03096},
pages = {535-555},
year = {2023},
abstract = {Tools for radiation exposure reconstruction are required to
support the medical management of radiation victims in
radiological or nuclear incidents. Different biological and
physical dosimetry assays can be used for various exposure
scenarios to estimate the dose of ionizing radiation a
person has absorbed. Regular validation of the techniques
through inter-laboratory comparisons (ILC) is essential to
guarantee high quality results. In the current RENEB
inter-laboratory comparison, the performance quality of
established cytogenetic assays [dicentric chromosome assay
(DCA), cytokinesis-block micronucleus assay (CBMN), stable
chromosomal translocation assay (FISH) and premature
chromosome condensation assay (PCC)] was tested in
comparison to molecular biological assays [gamma-H2AX foci
(gH2AX), gene expression (GE)] and physical dosimetry-based
assays [electron paramagnetic resonance (EPR), optically or
thermally stimulated luminescence (LUM)]. Three blinded
coded samples (e.g., blood, enamel or mobiles) were exposed
to 0, 1.2 or 3.5 Gy X-ray reference doses (240 kVp, 1
Gy/min). These doses roughly correspond to clinically
relevant groups of unexposed to low exposed (0-1 Gy),
moderately exposed (1-2 Gy, no severe acute health effects
expected) and highly exposed individuals (>2 Gy, requiring
early intensive medical care). In the frame of the current
RENEB inter-laboratory comparison, samples were sent to 86
specialized teams in 46 organizations from 27 nations for
dose estimation and identification of three clinically
relevant groups. The time for sending early crude reports
and more precise reports was documented for each laboratory
and assay where possible. The quality of dose estimates was
analyzed with three different levels of granularity, 1. by
calculating the frequency of correctly reported clinically
relevant dose categories, 2. by determining the number of
dose estimates within the uncertainty intervals recommended
for triage dosimetry (±0.5 Gy or ±1.0 Gy for doses <2.5 Gy
or >2.5 Gy), and 3. by calculating the absolute difference
(AD) of estimated doses relative to the reference doses. In
total, 554 dose estimates were submitted within the 6-week
period given before the exercise was closed. For samples
processed with the highest priority, earliest dose
estimates/categories were reported within 5-10 h of receipt
for GE, gH2AX, LUM, EPR, 2-3 days for DCA, CBMN and within
6-7 days for the FISH assay. For the unirradiated control
sample, the categorization in the correct clinically
relevant group (0-1 Gy) as well as the allocation to the
triage uncertainty interval was, with the exception of a few
outliers, successfully performed for all assays. For the 3.5
Gy sample the percentage of correct classifications to the
clinically relevant group (≥2 Gy) was between $89-100\%$
for all assays, with the exception of gH2AX. For the 1.2 Gy
sample, an exact allocation to the clinically relevant group
was more difficult and $0-50\%$ or $0-48\%$ of the estimates
were wrongly classified into the lowest or highest dose
categories, respectively. For the irradiated samples, the
correct allocation to the triage uncertainty intervals
varied considerably between assays for the 1.2 Gy
$(29-76\%)$ and 3.5 Gy $(17-100\%)$ samples. While a
systematic shift towards higher doses was observed for the
cytogenetic-based assays, extreme outliers exceeding the
reference doses 2-6 fold were observed for EPR, FISH and GE
assays. These outliers were related to a particular material
examined (tooth enamel for EPR assay, reported as kerma in
enamel, but when converted into the proper quantity, i.e. to
kerma in air, expected dose estimates could be recalculated
in most cases), the level of experience of the teams (FISH)
and methodological uncertainties (GE). This was the first
RENEB ILC where everything, from blood sampling to
irradiation and shipment of the samples, was organized and
realized at the same institution, for several biological and
physical retrospective dosimetry assays. Almost all assays
appeared comparably applicable for the identification of
unexposed and highly exposed individuals and the allocation
of medical relevant groups, with the latter requiring
medical support for the acute radiation scenario simulated
in this exercise. However, extreme outliers or a systematic
shift of dose estimates have been observed for some assays.
Possible reasons will be discussed in the assay specific
papers of this special issue. In summary, this ILC clearly
demonstrates the need to conduct regular exercises to
identify research needs, but also to identify technical
problems and to optimize the design of future ILCs},
cin = {S-US},
ddc = {530},
cid = {I:(DE-Juel1)S-US-20090406},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {37310880},
UT = {WOS:001004143500002},
doi = {10.1667/RADE-22-00207.1},
url = {https://juser.fz-juelich.de/record/1010513},
}